Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soquelitinib in Moderate to Severe Atopic Dermatitis
NCT06345404Phase 1Completed
- Sponsor
- Corvus Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing Soquelitinib with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 30 days. Started Apr 2024; status: completed.
02
Drugs
soquelitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06345404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345404.